Alprostadil (Caverject/MUSE): History and Development

The Prostaglandin E1 Discovery That Started It All

Alprostadil's story begins with basic lipid biochemistry in the 1930s and 1940s, when Ulf von Euler identified prostaglandins in human seminal fluid and prostate tissue. By the 1960s, Sune Bergström and Bengt Samuelsson had isolated and characterized the individual prostaglandin subtypes, work that earned them the 1982 Nobel Prize in Physiology or Medicine alongside John Vane 1. Prostaglandin E1 (PGE1) drew particular attention because of its potent vasodilatory and smooth muscle-relaxant properties.

The compound's first medical application had nothing to do with erections. Neonatologists used intravenous PGE1 starting in the 1970s to maintain patent ductus arteriosus in neonates with ductal-dependent congenital heart defects 2. That clinical experience proved PGE1 could be manufactured, standardized, and administered safely, establishing the pharmacological groundwork for its later urological use.

What connected prostaglandins to penile physiology was the observation that PGE1 caused dose-dependent relaxation of isolated human cavernosal smooth muscle strips in laboratory settings. Researchers recognized that if a vasodilator could relax trabecular smooth muscle and increase arterial inflow to the corpora cavernosa, it could produce an erection on demand. That hypothesis set the stage for one of the most significant clinical experiments in sexual medicine history.

Virag and Brindley: The Injection Era Begins (1982 to 1983)

Two physicians, working independently, transformed erectile dysfunction treatment in the early 1980s. In 1982, French vascular surgeon Ronald Virag reported that an accidental intracavernosal injection of papaverine during a vascular procedure produced a prolonged erection 3. He published his findings in The Lancet, describing papaverine injection as a potential diagnostic and therapeutic tool for impotence.

The moment that captured public attention came in 1983. British neurophysiologist Giles Brindley, at the American Urological Association meeting in Las Vegas, injected his own penis with phenoxybenzamine backstage, then walked onstage and dropped his trousers to demonstrate the resulting erection to a stunned audience 4. The demonstration was crude. It was also convincing. The era of pharmacological erection therapy had arrived.

These early agents (papaverine, phenoxybenzamine, phentolamine) worked but carried significant drawbacks: papaverine caused fibrosis in up to 30% of patients with prolonged use, and combination "trimix" regimens required compounding pharmacies 5. Researchers needed a cleaner molecule. PGE1 emerged as the leading candidate because it produced reliable erections with lower fibrosis risk and was metabolized locally in cavernosal tissue, limiting systemic side effects.

Alprostadil Enters the Clinic: 1986 to 1994

Hiroshi Ishii and colleagues in Japan were among the first to report intracavernosal PGE1 for erection induction in 1986. Shortly after, Helmut Porst in Germany and Adrian Zorgniotti in the United States published case series confirming that PGE1 injections produced erections sufficient for intercourse in men with organic erectile dysfunction 6.

The advantages over papaverine became clear quickly. PGE1 caused less corporal fibrosis. Priapism rates dropped to 1 to 3% compared with 6 to 10% for papaverine 7. Because alprostadil is rapidly metabolized by prostaglandin 15-hydroxy dehydrogenase within the corpus cavernosum, systemic cardiovascular effects were minimal. Penile pain at the injection site was the most common complaint, reported by 10 to 44% of users depending on the study and dose.

The Upjohn Company (later acquired by Pharmacia, then Pfizer) recognized the commercial potential and initiated the formal clinical development program for a standardized alprostadil injection formulation. The company designated the product Caverject and began Phase III trials in the early 1990s.

The Linet Trial and FDA Approval of Caverject (1995 to 1996)

The registration trial that secured Caverject's FDA approval was published by Owen Linet and Frances Ogrinc in the New England Journal of Medicine in 1996 8. This multicenter, double-blind, placebo-controlled study enrolled 296 men with erectile dysfunction of various etiologies (vasculogenic, neurogenic, psychogenic, and mixed).

The results were decisive. At optimized doses (mean dose approximately 17.8 mcg), 70% of alprostadil-treated patients achieved erections sufficient for intercourse, compared with 14% in the placebo group. Mean duration of erection was approximately 40 minutes. The study also documented the safety profile: penile pain occurred in 37% of injections (mostly mild, rated 1, 3 on a 10-point scale), and only 1% of patients experienced prolonged erections requiring intervention.

The FDA approved Caverject (alprostadil for injection) in July 1995 for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology 9. This was the first FDA-approved pharmacotherapy specifically indicated for erectile dysfunction. Before Caverject, the only options were vacuum erection devices, penile prosthesis implantation, or off-label papaverine/phentolamine injections.

Dr. Irwin Goldstein, a pioneer in sexual medicine at Boston University, noted at the time: "For the first time, we have a medication that can be prescribed with standardized dosing and a predictable safety profile for a condition that affects tens of millions of men." The approval changed how clinicians and patients conceptualized erectile dysfunction: from a surgical problem to a pharmacologically treatable condition.

MUSE: The Non-Needle Alternative (1997)

Many men willing to treat their ED were unwilling to inject their penis with a needle. VIVUS, Inc., a small pharmaceutical company based in Mountain View, California, developed the Medicated Urethral System for Erection (MUSE), a transurethral delivery system that used a small applicator to deposit an alprostadil pellet (125, 1 to 000 mcg) into the urethral meatus.

The concept relied on vascular communication between the urethra and the corpus spongiosum and corpora cavernosa. Alprostadil absorbed through the urethral mucosa would reach cavernosal tissue via venous channels. VIVUS conducted a large key trial: Padma-Nathan et al. published results in the New England Journal of Medicine in 1997, showing that 65.9% of men achieved erections sufficient for intercourse in-clinic, though the at-home success rate was lower at approximately 50% 10.

The FDA approved MUSE in November 1997. It offered a needle-free alternative, but came with trade-offs. Urethral burning or pain occurred in approximately 33% of users. Hypotension and dizziness affected 1.9 to 3.3% of patients, a higher rate than intracavernosal injection because urethral absorption allowed more systemic distribution 11. The larger alprostadil doses required (up to 1 to 000 mcg vs. 40 mcg for injection) reflected the less efficient delivery route.

Mechanism of Action: How Alprostadil Produces an Erection

Alprostadil binds to EP2 and EP4 prostaglandin receptors on cavernosal smooth muscle cells, activating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) 12. Elevated cAMP activates protein kinase A, which phosphorylates multiple downstream targets to reduce intracellular calcium concentrations. The result is smooth muscle relaxation in the trabecular meshwork and helicine arterioles of the corpora cavernosa.

This relaxation triggers a cascade. Arterial inflow increases. Expanding sinusoidal spaces compress subtunical venules against the tunica albuginea, trapping blood and producing rigidity. This veno-occlusive mechanism is the same physiological process that occurs during normal erection, but alprostadil initiates it pharmacologically rather than through neural signaling via the cavernous nerves.

The cAMP pathway is distinct from the cyclic guanosine monophosphate (cGMP) pathway targeted by PDE5 inhibitors like sildenafil 13. This distinction explains why alprostadil works in men who fail PDE5 inhibitors. PDE5 inhibitors require intact nitric oxide signaling to generate cGMP; alprostadil bypasses nitric oxide entirely, generating smooth muscle relaxation through a parallel second messenger system.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy for men with hypogonadism states: "Intracavernosal alprostadil or alprostadil urethral suppositories should be considered as second-line therapy for men with ED who do not respond to PDE5 inhibitors" 14.

The PDE5 Inhibitor Era: Alprostadil's Changing Role (1998, Present)

Sildenafil (Viagra) received FDA approval in March 1998, just months after MUSE. The oral pill was easier, less invasive, and effective for approximately 70% of men with ED. Caverject and MUSE prescriptions declined sharply. By 2002, sildenafil dominated the ED market, followed by tadalafil (Cialis, 2003) and vardenafil (Levitra, 2003).

But PDE5 inhibitors don't work for everyone. Approximately 30 to 40% of men with ED have an inadequate response to oral therapy, particularly those with diabetes, post-radical prostatectomy nerve damage, or severe vascular disease 15. For these patients, alprostadil injection remains a first-choice second-line treatment per the American Urological Association (AUA) 2018 guideline on erectile dysfunction 16.

Penile rehabilitation after radical prostatectomy represents another area where alprostadil retains clinical relevance. Low-dose intracavernosal alprostadil (5 to 10 mcg two to three times weekly) has been used in post-prostatectomy rehabilitation protocols to promote cavernosal oxygenation and prevent smooth muscle atrophy during the nerve recovery period, which can last 12 to 24 months 17.

Formulation Evolution: From Vials to Autoinjectors

The original Caverject required manual reconstitution: mixing lyophilized alprostadil powder with bacteriostatic water using a conventional syringe. This process intimidated patients and introduced dosing variability.

Pharmacia (which had acquired Upjohn) responded with Caverject Impulse, a dual-chamber prefilled delivery device approved in 2001. The device eliminated reconstitution by separating the powder and diluent in two chambers within the same cartridge. The patient simply twisted the plunger to mix, attached the needle, and dialed the dose 18. Edex (alprostadil alfadex), marketed by Auxilium Pharmaceuticals, offered another injection formulation with an alpha-cyclodextrin complexing agent for improved stability.

Generic alprostadil for injection became available after patent expiration, reducing costs. A single-dose Caverject Impulse kit costs approximately $40, 80 at U.S. retail pharmacies, while generic alprostadil vials can cost $15, 30 per dose, depending on pharmacy and insurance coverage. MUSE suppositories remain more expensive, typically $30, 60 per dose, partly because the transurethral delivery device is proprietary.

Combination Therapy and Compounding Innovations

When alprostadil monotherapy produces insufficient rigidity, clinicians often combine it with other vasoactive agents. The most common combination is "trimix" (alprostadil + papaverine + phentolamine), which targets three distinct smooth muscle relaxation pathways simultaneously 19. Trimix is not FDA-approved as a combination product and must be compounded by specialty pharmacies, but it has become standard practice in sexual medicine clinics.

"Bimix" (papaverine + phentolamine, without alprostadil) is sometimes used for cost reduction, and "quadmix" adds atropine or vasoactive intestinal peptide (VIP) for refractory cases. These compounded formulations exist because no manufacturer has pursued FDA registration for the combinations, given the relatively small market size compared with oral PDE5 inhibitors.

Topical alprostadil cream (Vitaros, marketed in Europe and Canada) received approval from the European Medicines Agency and Health Canada but has not been approved by the FDA for the U.S. market 20. The cream, applied to the glans penis, showed efficacy rates of approximately 36 to 43% in clinical trials, lower than injection or MUSE but appealing for its non-invasive application.

Current Clinical Position and Ongoing Research

Alprostadil occupies a well-defined niche in the 2024 AUA/SMSNA guideline framework for erectile dysfunction management. It is the recommended second-line pharmacotherapy when oral PDE5 inhibitors fail or are contraindicated (e.g., in patients taking nitrates for coronary artery disease). Third-line options include penile prosthesis implantation and, in select cases, low-intensity shockwave therapy, though evidence for the latter remains mixed 21.

Research into improved alprostadil delivery continues. Nanoparticle-encapsulated PGE1 formulations are being studied to extend duration of action and reduce injection site pain 22. Biodegradable microsphere depot injections could theoretically allow less frequent dosing, though none have reached Phase III trials.

Three decades after Caverject's approval, alprostadil remains the only FDA-approved injectable specifically indicated for erectile dysfunction. Its dual mechanism of direct smooth muscle relaxation and independence from the nitric oxide/cGMP pathway ensures continued clinical utility for the estimated 30% of ED patients who cannot rely on oral medications alone.